Octreotide (drug)

Lahore General Hospital · FDA-approved active Small molecule

Octreotide (drug) is a Somatostatin analog Small molecule drug developed by Lahore General Hospital. It is currently FDA-approved for Acromegaly, Variceal bleeding in portal hypertension, Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma). Also known as: Octreotide acetate, Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®), Sandostatin®, Somatostatin analogue.

Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.

Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors. Used for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome.

At a glance

Generic name	Octreotide (drug)
Also known as	Octreotide acetate, Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®), Sandostatin®, Somatostatin analogue
Sponsor	Lahore General Hospital
Drug class	Somatostatin analog
Target	Somatostatin receptors (SSTR2, SSTR5)
Modality	Small molecule
Therapeutic area	Oncology; Endocrinology
Phase	FDA-approved

Mechanism of action

Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, while also causing vasoconstriction that reduces blood supply to tumors. These dual effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.

Approved indications

• Acromegaly
• Variceal bleeding in portal hypertension
• Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma)
• Thyroid storm

Common side effects

• Abdominal pain/discomfort
• Diarrhea
• Nausea
• Gallstone formation (cholelithiasis)
• Hyperglycemia
• Injection site pain
• Headache

Key clinical trials

• Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
• Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
• Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (PHASE2)
• Octreotide Microspheres for Preventing Pancreatic Fistula (PHASE3)
• Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (PHASE3)
• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Octreotide (drug) CI brief — competitive landscape report
• Octreotide (drug) updates RSS · CI watch RSS
• Lahore General Hospital portfolio CI

Frequently asked questions about Octreotide (drug)

What is Octreotide (drug)?

Octreotide (drug) is a Somatostatin analog drug developed by Lahore General Hospital, indicated for Acromegaly, Variceal bleeding in portal hypertension, Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma).

How does Octreotide (drug) work?

Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.

What is Octreotide (drug) used for?

Octreotide (drug) is indicated for Acromegaly, Variceal bleeding in portal hypertension, Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma), Thyroid storm.

Who makes Octreotide (drug)?

Octreotide (drug) is developed and marketed by Lahore General Hospital (see full Lahore General Hospital pipeline at /company/lahore-general-hospital).

Is Octreotide (drug) also known as anything else?

Octreotide (drug) is also known as Octreotide acetate, Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®), Sandostatin®, Somatostatin analogue.

What drug class is Octreotide (drug) in?

Octreotide (drug) belongs to the Somatostatin analog class. See all Somatostatin analog drugs at /class/somatostatin-analog.

What development phase is Octreotide (drug) in?

Octreotide (drug) is FDA-approved (marketed).

What are the side effects of Octreotide (drug)?

Common side effects of Octreotide (drug) include Abdominal pain/discomfort, Diarrhea, Nausea, Gallstone formation (cholelithiasis), Hyperglycemia, Injection site pain.

What does Octreotide (drug) target?

Octreotide (drug) targets Somatostatin receptors (SSTR2, SSTR5) and is a Somatostatin analog.

Related

• Drug class: All Somatostatin analog drugs
• Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
• Manufacturer: Lahore General Hospital — full pipeline
• Therapeutic area: All drugs in Oncology; Endocrinology
• Indication: Drugs for Acromegaly
• Indication: Drugs for Variceal bleeding in portal hypertension
• Indication: Drugs for Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma)
• Also known as: Octreotide acetate, Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®), Sandostatin®, Somatostatin analogue